Search

Your search keyword '"Usmani, Saad Z"' showing total 9 results
Start Over Author "Usmani, Saad Z" Journal british journal of haematology
9 results on '"Usmani, Saad Z"'

1. Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

Author

Nooka, Ajay K., primary, Kaufman, Jonathan L., additional, Rodriguez, Cesar, additional, Jakubowiak, Andrzej, additional, Efebera, Yvonne, additional, Reeves, Brandi, additional, Wildes, Tanya M., additional, Holstein, Sarah A., additional, Anderson, Larry D., additional, Badros, Ashraf, additional, Shune, Leyla, additional, Chari, Ajai, additional, Pei, Huiling, additional, Cortoos, Annelore, additional, Patel, Sharmila, additional, Lin, Thomas S., additional, Voorhees, Peter M., additional, Usmani, Saad Z., additional, and Richardson, Paul G., additional

Published
2024
Full Text
View/download PDF

3. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

Author

Quach, Hang, primary, Nooka, Ajay, additional, Samoylova, Olga, additional, Venner, Christopher P., additional, Kim, Kihyun, additional, Facon, Thierry, additional, Spencer, Andrew, additional, Usmani, Saad Z., additional, Grosicki, Sebastian, additional, Suzuki, Kenshi, additional, Delimpasi, Sosana, additional, Weisel, Katja, additional, Obreja, Mihaela, additional, Zahlten‐Kumeli, Anita, additional, and Mateos, Maria‐Victoria, additional

Published
2021
Full Text
View/download PDF

4. Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

Author

Rosiñol, Laura, primary, Beksac, Meral, additional, Zamagni, Elena, additional, Van de Donk, Niels W. C. J., additional, Anderson, Kenneth C., additional, Badros, Ashraf, additional, Caers, Jo, additional, Cavo, Michele, additional, Dimopoulos, Meletios‐Athanasios, additional, Dispenzieri, Angela, additional, Einsele, Hermann, additional, Engelhardt, Monika, additional, Fernández de Larrea, Carlos, additional, Gahrton, Gösta, additional, Gay, Francesca, additional, Hájek, Roman, additional, Hungria, Vania, additional, Jurczyszyn, Artur, additional, Kröger, Nicolaus, additional, Kyle, Robert A., additional, Leal da Costa, Fernando, additional, Leleu, Xavier, additional, Lentzsch, Suzanne, additional, Mateos, Maria V., additional, Merlini, Giampaolo, additional, Mohty, Mohamad, additional, Moreau, Philippe, additional, Rasche, Leo, additional, Reece, Donna, additional, Sezer, Orhan, additional, Sonneveld, Pieter, additional, Usmani, Saad Z., additional, Vanderkerken, Karin, additional, Vesole, David H., additional, Waage, Anders, additional, Zweegman, Sonja, additional, Richardson, Paul G., additional, and Bladé, Joan, additional

Published
2021
Full Text
View/download PDF

5. Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma

Author

Hussain, M. Junaid, primary, Robinson, Myra M., additional, Hamadeh, Issam, additional, Arnall, Justin, additional, Bhutani, Manisha, additional, Atrash, Shebli, additional, Friend, Reed, additional, Pineda‐Roman, Mauricio, additional, Symanowski, James T., additional, Usmani, Saad Z., additional, and Voorhees, Peter M., additional

Published
2018
Full Text
View/download PDF

6. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

Author

van de Donk, Niels W. C. J., primary, Casneuf, Tineke, additional, Di Cara, Alessandro, additional, Parren, Paul W., additional, Zweegman, Sonja, additional, van Kessel, Berris, additional, Lokhorst, Henk M., additional, Usmani, Saad Z., additional, Lonial, Sagar, additional, Richardson, Paul G., additional, Chiu, Christopher, additional, Mutis, Tuna, additional, Nijhof, Inger S., additional, and Sasser, A. Kate, additional

Published
2018
Full Text
View/download PDF

7. Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.

Author

Hussain, M. Junaid, Robinson, Myra M., Hamadeh, Issam, Arnall, Justin, Bhutani, Manisha, Atrash, Shebli, Friend, Reed, Pineda‐Roman, Mauricio, Symanowski, James T., Usmani, Saad Z., and Voorhees, Peter M.

Subjects
MULTIPLE myeloma, THALIDOMIDE, BORTEZOMIB, T helper cells, CYTOTOXIC T cells, KILLER cells
Abstract

The article focuses on the role of Daratumumab, pomalidomide and dexamethasone (Pd) combination therapy for the treatment of relapsed and refractory multiple myeloma. It mentions the addition of daratumumab to the Pd backbone (DaraPd) for the patients with relapsed and refractory multiple myelom and also discussions on daratumumab that depletes levels of CD38 (cluster of differentiation 38).

Published
2019
Full Text
View/download PDF

8. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

Author

Donk, Niels W. C. J., Casneuf, Tineke, Di Cara, Alessandro, Parren, Paul W., Zweegman, Sonja, Kessel, Berris, Lokhorst, Henk M., Usmani, Saad Z., Lonial, Sagar, Richardson, Paul G., Chiu, Christopher, Mutis, Tuna, Nijhof, Inger S., and Sasser, A. Kate

Abstract

The article informs on a study for analysing the impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. It examines effect of Fc portion of IgG polymorphisms on response, survival, and infusion-related reactions in multiple myeloma patients treated with daratumumab drug as single agent in the GEN501 and SIRIUS studies.

Published
2019
Full Text
View/download PDF

9. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

Author

van de Donk NWCJ, Casneuf T, Di Cara A, Parren PW, Zweegman S, van Kessel B, Lokhorst HM, Usmani SZ, Lonial S, Richardson PG, Chiu C, Mutis T, Nijhof IS, and Sasser AK

Subjects
Antibodies, Monoclonal adverse effects, Disease-Free Survival, Female, Humans, Male, Polymorphism, Genetic, Survival Rate, Antibodies, Monoclonal administration & dosage, Multiple Myeloma drug therapy, Multiple Myeloma genetics, Multiple Myeloma mortality, Neoplasm Proteins genetics, Receptors, IgG genetics
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results